Wednesday, January 23, 2008

Cuadra reportedly on prescription Abilify med to cope with anticipated "principal killer" accusation

PROSECUTORS IN KOCIS-CUADRA-KEREKES CASE PLAY MIND GAMES WITH THE DEFENSE AS HARLOW IS ALLEGEDLY PRESCRIBED "ABILIFY" MED

Everything now depends on the January 30th hearing, as my sources inform me that both defendants Harlow Cuadra and Joseph Kerekes are in a "state of constant agitation and high anxiety" and that the psychotropic prescription drug "Abilify" may have been prescribed for Harlow Cuadra to "modify his increasingly erratic and depressive mood swings" according to my sources.

No doubt it's increasingly dawning on him that his former boyfriend Kerekes has already pointed the finger at him as being the so-called "principal killer" and thus the primary target of prosecutors for the execution gurney.

Says the Times-Leader in this revealing excerpt on January 22:

http://www.timesleader.com/news/20080123_23kerekes_dw_ART.html

Prosecutors are seeking the death penalty for both suspects.

One of Kerekes’ attorneys, Mark Bufalino, had previously asked a judge to force prosecutors to reveal whether they believe Kerekes was the principal or accomplice. Bufalino needs to know, he said, because he believes it is legal to only seek the death penalty for a principal killer.
If prosecutors do not believe Kerekes is the principal killer, Bufalino indicated he could ask that prosecutors be barred from seeking the death penalty for Kerekes.

Luzerne County Assistant District Attorney Mike Melnick has said evidence in the case “fully suggests” both suspects could be principals in the case.

And in the court papers filed Tuesday by a team of prosecutors, they said they should not have to reveal who they believe is the principal killer and accomplice because “different inferences might reasonably be drawn from the evidence as to who nearly decapitated Mr. Kocis.” It should be a jury’s job, the prosecutors said, to determine principal and accomplice.

Court of Common Pleas Judge Peter Paul Olszewski Jr. will decide after a Jan. 30 hearing.